Recombinant Staphylococcus aureus Protein flp (flp)

How does Protein Flp relate to other virulence factors in S. aureus?

S. aureus expresses several key virulence factors that contribute to its pathogenicity, including FnBP and ClfA. While Flp has distinct functions, researchers should understand the interplay between these factors when designing comprehensive studies:

FnBP and ClfA have been shown to promote S. aureus adhesion to breast tissue and are important targets for vaccine development. Antibodies induced against these proteins can partially block bacterial adhesion .

What bioinformatic approaches can be used to predict epitopes and structural features of Protein Flp?

Researchers can employ multiple computational approaches to predict immunogenic and structural features of Protein Flp:

• For B-cell epitope prediction, the Kolaskar and Tongaonkar method (available at http://imed.med.ucm.es/Tools/antigenic.pl) is recommended based on validated research protocols.

• Signal peptide prediction can be conducted using SignalP 5.0 Server (http://www.cbs.dtu.dk/services/SignalP/).

• Tertiary structure prediction can be performed using Phyre2 software (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index).

When analyzing potential epitopes, researchers should examine propensity indices (values >0.9 typically indicate good candidates) and consider multiple epitopes to ensure comprehensive coverage for immunological studies .

What are the optimal conditions for reconstitution and storage of recombinant Protein Flp?

For optimal handling of recombinant Protein Flp, follow these research-validated protocols:

Reconstitution Protocol:

• Centrifuge the vial briefly before opening to ensure all material is at the bottom.

• Reconstitute the lyophilized protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.

• Add glycerol to a final concentration of 5-50% (recommended 50%) for long-term storage stability.

• Aliquot the reconstituted protein to minimize freeze-thaw cycles.

Storage Conditions:

• Store lyophilized protein at -20°C/-80°C upon receipt.

• Store reconstituted working aliquots at 4°C for up to one week.

• For long-term storage, keep aliquots at -20°C/-80°C.

• Avoid repeated freeze-thaw cycles as these significantly impact protein stability and activity.

The protein is typically supplied in a Tris/PBS-based buffer with 6% Trehalose at pH 8.0, which helps maintain stability during storage .

How can researchers confirm direct binding of compounds to S. aureus proteins in cellular contexts?

To verify compound-protein interactions in cellular contexts, the Cellular Thermal Shift Assay (CETSA) has proven effective in recent S. aureus protein research:

CETSA Protocol for S. aureus Proteins:

• Culture S. aureus strain (e.g., 8325-4) with your compound of interest (typically at 10 μM concentration).

• Process cells according to standard CETSA protocols.

• Analyze thermal stability shifts of the target protein.

• Include appropriate controls (DMSO vehicle and known binders).

A significant increase in the thermal stability (Tm) of the target protein indicates direct binding of the compound to the protein in the cellular environment. This method has been successfully employed to demonstrate binding of compounds like (R)- and (S)-ZG197 to ClpP in S. aureus cells .

What expression systems are most effective for producing functional recombinant Protein Flp?

E. coli is the established expression system for producing recombinant S. aureus Protein Flp with high yield and purity. The methodological approach includes:

Expression Optimization:

• Clone the flp gene into an appropriate expression vector (pET28a or pET32a are commonly used).

• Transform the construct into a compatible E. coli strain.

• Induce protein expression under optimized conditions.

• Purify using affinity chromatography targeting the His-tag.

For enhanced solubility and function, researchers should consider:

• Using BL21(DE3) or Rosetta strains for expression

• Optimizing induction temperature (typically 16-25°C for membrane proteins)

• Adding solubility enhancers such as sorbitol or trehalose to the growth medium

• Including appropriate detergents during purification if working with the full-length protein including transmembrane domains

How can Protein Flp be incorporated into multi-antigen constructs for vaccine development?

Recent research demonstrates successful approaches for incorporating S. aureus proteins into multi-antigen constructs:

Design Strategy for Fusion Constructs:

• Identify immunogenic epitopes using bioinformatic prediction tools.

• Select protein fragments with optimal immunogenicity.

• Engineer constructs with appropriate linker sequences (-GGGGSGGGGSGGGGS-) to maintain proper folding of each domain.

• Express and purify the fusion proteins using established protocols.

This approach has been successfully applied to create fusion proteins combining virulence factors from S. aureus (FnBP and ClfA) with those from S. agalactiae (GapC and Sip). The resulting chimeric proteins induced high antibody levels in mice and provided protection against bacterial challenge .

When designing fusion constructs including Protein Flp, researchers should carefully analyze its epitope structure and consider its incorporation with other relevant S. aureus virulence factors for comprehensive coverage.

What methods can be used to evaluate the functional activity of recombinant Protein Flp?

To assess the functional activity of recombinant Protein Flp, researchers can employ several complementary approaches:

In vitro Activity Assays:

• Protein-protein interaction studies using surface plasmon resonance (SPR)

• Enzymatic activity assays if specific enzymatic functions are identified

• Binding assays to potential substrates or interaction partners

Cellular Functional Assays:

• Bacterial adhesion assays to relevant cell types

• Biofilm formation assessment in the presence/absence of anti-Flp antibodies

• Cell invasion assays to determine the contribution of Flp to virulence

Immunological Assessment:

• Antibody production evaluation following immunization with recombinant Flp

• Protection studies in appropriate animal models

• Neutralization assays to determine if anti-Flp antibodies can block specific functions

These methodological approaches have been applied successfully to other S. aureus virulence factors and can be adapted for Protein Flp research .

How can researchers develop selective modulators of S. aureus proteins while avoiding cross-reactivity with human homologs?

A structure-based design approach has proven successful for developing selective modulators of S. aureus proteins:

Structure-Based Design Methodology:

• Identify structural differences between bacterial and human protein homologs.

• Focus on key structural elements that contribute to species selectivity.

• Design compounds that exploit these differences.

• Validate selectivity through comparative binding and functional assays.

Recent research has identified the importance of specific structural elements in human ClpP, particularly W146 and its interaction with the C-terminal motif, which significantly contribute to discriminating between bacterial and human activators. This approach led to the development of (R)- and (S)-ZG197 as highly selective S. aureus ClpP activators .

For Protein Flp research, similar structure-based approaches could be employed to develop selective modulators, particularly if structural data becomes available.

What are common challenges in purifying functional recombinant Protein Flp and how can they be addressed?

Researchers working with recombinant Protein Flp may encounter several challenges during purification:

For membrane-associated proteins like Flp, inclusion of appropriate detergents during extraction and purification is particularly critical for maintaining native conformation and function .

How can immunization protocols with recombinant S. aureus proteins be optimized for maximum efficacy?

Based on successful approaches with S. aureus protein immunization, researchers should consider the following protocol optimizations:

Immunization Protocol Optimization:

• Adjuvant selection: Freund's complete adjuvant for primary immunization followed by incomplete adjuvant for boosters has shown efficacy in mouse models.

• Dosing schedule: Primary immunization followed by 2-3 boosters at 2-week intervals.

• Antigen concentration: 50-100 μg per immunization for mice has demonstrated good antibody responses.

• Route of administration: Subcutaneous or intraperitoneal administration depending on the experimental design.

Assessment of Immune Response:

• Measure antibody titers using ELISA 7-10 days after the final boost.

• Assess functional activity of antibodies through neutralization assays.

• Evaluate protection through bacterial challenge models.

In mouse studies with chimeric S. aureus proteins, this approach induced high antibody levels and provided significant protection against bacterial challenge, with reduced bacterial loads in the spleen and liver following infection .

How can researchers address experimental inconsistencies when comparing in vitro and in vivo results with S. aureus proteins?

When confronting discrepancies between in vitro and in vivo findings, researchers should consider these methodological approaches:

Systematic Troubleshooting Framework:

• Evaluate protein quality: Confirm proper folding and activity of the recombinant protein using biophysical and functional assays.

• Review experimental conditions: Assess whether in vitro conditions appropriately mimic physiological environments.

• Consider host factors: Analyze the contribution of host-specific factors absent in in vitro systems.

• Examine dosing parameters: Ensure that concentrations used in vitro are achievable and relevant in vivo.

Bridging Strategies:

• Implement ex vivo models as intermediary systems between in vitro and in vivo studies.

• Use multiple animal models to validate findings and account for species-specific differences.

• Conduct comprehensive pharmacokinetic studies to understand protein behavior in vivo.

Research with other S. aureus virulence factors has demonstrated that fusion proteins effective in inducing antibody responses in vitro also provided protection in mouse challenge models, suggesting that well-designed recombinant proteins can bridge in vitro to in vivo translation successfully .